American Joint Committee on Cancer prognostic factors consensus conference.
about
Contemporary Management of Prostate CancerLC-MS/MS quantification of sulfotransferases is better than conventional immunogenic methods in determining human liver SULT activities: implication in precision medicine.American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.Prognostic biomarkers in ovarian cancer.Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer.Guidelines 2000 for colon and rectal cancer surgery.Will early detection of non-axillary sentinel nodes affect treatment decisions?Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.Clinical infrastructures to support proteomic studies of tissue and fluids in breast cancer.Epigenomics of ovarian cancer and its chemoprevention.Merging claims databases with a tumor registry to evaluate variations in cancer mortality: results from a pilot study of 698 colorectal cancer patients treated at one hospital in the 1990s.AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conferenceCell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancerAssessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratificatNotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.Telomeres: prognostic markers for solid tumors.Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patientsPrognostic Impact of Changes in Adipose Tissue Areas after Colectomy in Colorectal Cancer Patients.Comparison of the 7(th) and proposed 8(th) editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery.Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions.Novel molecular prognostic markers in breast cancer.Novel automated three-dimensional genome scanning based on the nuclear architecture of telomeres.Clinicopathological significance of glucose transporter protein-1 overexpression in human osteosarcoma.Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma.Expression and immunogenicity of NY-ESO-1 in colorectal cancer.Breast cancer prognostication in the 21st century and the Nottingham prognostic index.Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation.Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer.Preserved Axin expression is associated with an aggressive phenotype in invasive breast carcinomas.Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer.Combination of carcinoembryonic antigen with the American Joint Committee on Cancer TNM staging system in rectal cancer: a real-world and large population-based study
P2860
Q26767456-C741B681-28EF-4AC8-8E5E-16EB903B122AQ33818825-8519E3A6-51FA-4FB4-A0B0-3D62D61C26E9Q33875909-7A3DEC3C-1488-43C1-B335-FA23A7513AC5Q34086636-5845E292-9533-48E2-94BB-06830B727B9BQ34119630-7D31D67D-E56C-4F65-8012-A424326F7D8DQ34222930-AE5A209C-1EDC-443D-BD3A-5A5F2E431F79Q34859352-A87370D7-6791-41C8-90F0-5E9891D52F17Q35208414-A627C92B-50A9-4A99-BA02-02F9DF95D741Q35648512-D7BBF2EB-C958-4FDA-A52E-0300536CF224Q35711392-32EB9941-EA8D-46F6-B80F-8457B60CC9B1Q35806743-4311B13C-8C58-4E3B-8038-03F3BDFF8EEEQ36063236-4D0A3173-EAE1-4BBF-B3BF-A4FD4463D976Q36085418-DE8B45DF-DBE1-4343-AFEA-9BF82BE9DFCDQ36133745-6A646460-2701-40DE-A044-E85D975E838DQ36396570-A50DA8FA-54C1-40FB-859C-E2364071F4EFQ36542887-B14C7C34-4EC7-4C8E-87CA-64E3BC024C0BQ36624145-ACE152D5-FC16-4397-8A60-3A5AEB2B79CDQ37207970-83DABAEA-8F57-4D49-9CE9-D4521B27C8B9Q37264472-135CA1FD-6A65-48E5-A54C-2F98ECB8BC31Q37965553-68B4B24B-4F59-435A-B94F-7377F369930EQ38089820-F6F1E36D-B54A-42A7-A890-5B183B7C10D5Q39603154-C43215F8-B7E1-4A55-AC6A-4C194E44C8FEQ41145138-F2D37ED1-678B-40DE-A98F-9F5FAED51AB9Q41813299-18A3CD0F-5564-4C15-84C0-E70989756FA9Q42235384-786499A1-2E86-4807-8560-242F8989A2AEQ43011646-07EA1458-1E2E-49A0-B1BE-66C218787B9CQ43921569-B5B93F6A-C69F-45D6-873E-21202A0CAD5DQ51099923-AE12A72F-E8AD-4C35-A449-0E054A0DF25FQ54461214-A3A9A497-73A6-4576-A935-57CEDA316204Q54694698-6B3F23A2-ADD8-44F9-94D3-F52805844ABAQ55287323-EAECE0AB-1113-4186-A221-135BDEB444A1Q57111610-A11A1F7B-69CF-4A72-B044-A3B267031FE0
P2860
American Joint Committee on Cancer prognostic factors consensus conference.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
American Joint Committee on Cancer prognostic factors consensus conference.
@ast
American Joint Committee on Cancer prognostic factors consensus conference.
@en
type
label
American Joint Committee on Cancer prognostic factors consensus conference.
@ast
American Joint Committee on Cancer prognostic factors consensus conference.
@en
prefLabel
American Joint Committee on Cancer prognostic factors consensus conference.
@ast
American Joint Committee on Cancer prognostic factors consensus conference.
@en
P2093
P2860
P1433
P1476
American Joint Committee on Cancer prognostic factors consensus conference.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1097-0142(19991201)86:11<2436::AID-CNCR35>3.0.CO;2-#
P407
P577
1999-12-01T00:00:00Z